Brokerages Set Teleflex Incorporated (NYSE:TFX) PT at $164.63

Shares of Teleflex Incorporated (NYSE:TFX) have been assigned a consensus rating of “Hold” from the eleven brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $164.63.

TFX has been the subject of a number of research reports. Royal Bank Of Canada dropped their price objective on Teleflex from $150.00 to $145.00 and set a “sector perform” rating for the company in a research note on Friday, May 2nd. Mizuho set a $155.00 price objective on Teleflex in a research note on Wednesday, April 16th. Citizens Jmp cut Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. Wall Street Zen raised Teleflex from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $140.00 price objective (down from $255.00) on shares of Teleflex in a research note on Friday, February 28th.

Teleflex Price Performance

TFX stock opened at $118.03 on Wednesday. Teleflex has a 52-week low of $116.60 and a 52-week high of $249.91. The company has a quick ratio of 1.32, a current ratio of 2.28 and a debt-to-equity ratio of 0.44. The business has a fifty day moving average of $125.44 and a two-hundred day moving average of $150.14. The stock has a market cap of $5.22 billion, a price-to-earnings ratio of 37.23, a price-to-earnings-growth ratio of 1.84 and a beta of 1.10.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.88 by $0.03. Teleflex had a return on equity of 14.73% and a net margin of 4.96%. The business had revenue of $700.67 million during the quarter, compared to analysts’ expectations of $699.37 million. During the same period in the previous year, the firm posted $3.21 earnings per share. The company’s revenue was down 5.0% on a year-over-year basis. As a group, research analysts anticipate that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 16th. Investors of record on Tuesday, May 20th were issued a $0.34 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $1.36 dividend on an annualized basis and a yield of 1.15%. Teleflex’s dividend payout ratio (DPR) is presently 42.90%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CANADA LIFE ASSURANCE Co boosted its holdings in Teleflex by 0.4% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 20,320 shares of the medical technology company’s stock valued at $3,614,000 after purchasing an additional 74 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in Teleflex by 103.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 100 shares during the period. True Wealth Design LLC lifted its holdings in Teleflex by 62.3% during the 4th quarter. True Wealth Design LLC now owns 271 shares of the medical technology company’s stock worth $48,000 after buying an additional 104 shares during the last quarter. Isthmus Partners LLC lifted its holdings in Teleflex by 7.3% during the 4th quarter. Isthmus Partners LLC now owns 1,535 shares of the medical technology company’s stock worth $273,000 after buying an additional 105 shares during the last quarter. Finally, QRG Capital Management Inc. lifted its holdings in Teleflex by 5.8% during the 4th quarter. QRG Capital Management Inc. now owns 2,178 shares of the medical technology company’s stock worth $388,000 after buying an additional 119 shares during the last quarter. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.